文献速递临床试验与 GCP

泼尼松龙与多西环素治疗不明病因急性间质性肾炎的随机对照试验

Randomized control trial of prednisolone and doxycycline in patients with acute interstitial nephritis of unknown aetiology.
PubMed 文献 · Trials · 2023-01-05

该随机对照试验采用2×2析因设计,纳入59例不明病因急性间质性肾炎患者,比较泼尼松龙、多西环素、两药联用及均不使用的效果。主要结局为6个月时eGFR恢复情况,结果显示各组间无显著差异。探索性分析中,泼尼松龙治疗组无进展生存优于未治疗组(log-rank P=0.02),但多西环素组无此差异。

要点

  • 泼尼松龙和多西环素在6个月时对不明病因急性间质性肾炎的肾功能恢复无显著获益。
  • 探索性分析中泼尼松龙治疗组无进展生存优于未治疗组,log-rank检验P=0.02。
  • 多西环素治疗组与未治疗组无进展生存无显著差异,P=0.60。

核心结论

  • 泼尼松龙和多西环素对不明病因急性间质性肾炎(可能是不明病因慢性肾脏病的最早表现)在6个月时无获益。
  • 泼尼松龙对不明病因慢性肾脏病的长期结局可能有潜在获益。
  • 需要一项有足够把握度的类固醇试验,以3年内eGFR降至<30 ml/min/1.73m2作为结局指标,针对不明病因急性间质性肾炎开展。

研究设计与样本

  • 随机临床试验,采用2×2析因设计,纳入59例不明病因急性间质性肾炎患者。
  • 分组:A组泼尼松龙15例,B组多西环素15例,C组两药联用14例,D组两药均不用15例。
  • 主要结局为6个月时eGFR恢复至61-90 ml/min/1.73m2(完全缓解)、31-60 ml/min/1.73m2(部分缓解)或0-30 ml/min/1.73m2(无缓解)。
  • 次要结局为6-36个月无进展生存(未达到eGFR<30 ml/min/1.73m2)。
  • 分析采用意向性治疗分析。

主要发现

  • 6个月时完全缓解、部分缓解、无缓解例数分别为:A组3:8:2,B组2:8:3,C组8:5:0,D组8:6:1。
  • A组与D组比较P=0.2,B组与D组比较P=0.1,C组与D组比较P=0.4,均无显著差异。
  • 探索性分析中,泼尼松龙治疗组(A+C)无进展生存为0/29(100%),未接受泼尼松龙组(B+D)为25/30(83%),log-rank检验P=0.02。
  • 多西环素治疗组(B+C)无进展生存为27/29(93%),未接受多西环素组(A+D)为27/30(90%),log-rank检验P=0.60。

临床怎么用

  • 原文结论指出泼尼松龙和多西环素对不明病因慢性肾脏病最早表现于6个月时无获益。
  • 原文结论指出泼尼松龙对不明病因慢性肾脏病长期结局可能有潜在获益。
  • 原文结论提出需要一项有足够把握度的类固醇试验,以3年内eGFR降至<30 ml/min/1.73m2作为结局指标。

局限性

  • 原文结论指出需要一项有足够把握度的类固醇试验,以3年内eGFR降至<30 ml/min/1.73m2作为结局指标,针对不明病因急性间质性肾炎开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients presenting with acute interstitial nephritis (AIN) of unknown aetiology, probably the earliest presentation of chronic kidney disease of unknown aetiology (CKDu), have been treated with oral prednisolone and doxycycline by physicians in Sri Lanka. This trial assessed the effectiveness of prednisolone and doxycycline based on eGFR changes at 6 months in patients with AIN of unknown aetiology. METHOD: A randomized clinical trial with a 2 × 2 factorial design for patients presenting with AIN of unknown aetiology (n = 59) was enacted to compare treatments with; A-prednisolone, B-doxycycline, C-both treatments together, and D-neither. The primary outcome was a recovery of patients' presenting renal function to eGFR categories: 61-90 ml/min/1.73m2 (complete remission- CR) to 31-60 ml/min/1.73m2 (partial remission- PR) and 0-30 ml/min/1.73m2 no remission (NR) by 6 months. A secondary outcome was progression-free survival (not reaching < 30 ml/min/1.73m2 eGFR), by 6-36 months. Analysis was by intention to treat. RESULTS: Seventy patients compatible with a clinical diagnosis of AIN were biopsied for eligibility; 59 AIN of unknown aetiology were enrolled, A = 15, B = 15, C = 14 and D = 15 randomly allocated to each group. Baseline characteristics were similar between groups. The number of patients with CR, PR and NR, respectively, by 6 months, in group A 3:8:2, group B 2:8:3 and group C 8:5:0 was compared with group D 8:6:1. There were no significant differences found between groups A vs. D (p = 0.2), B vs. D (p = 0.1) and C vs. D (p = 0.4). In an exploratory analysis, progression-free survival in prednisolone-treated (A + C) arms was 0/29 (100%) in comparison to 25/30 (83%) in those not so treated (B + D) arms, and the log-rank test was p = 0.02, whereas no such difference found (p = 0.60) between doxycycline-treated (B + C) arms 27/29 (93%) vs those not so treated (A + D) arms 27/30 (90%). CONCLUSION: Prednisolone and doxycycline were not beneficial for the earliest presentation of CKDu at 6 months. However, there is a potential benefit of prednisolone on the long-term outcome of CKDu. An adequately powered steroid trial using patients reaching < 30 ml/min/1.73m2 eGFR by 3 years, as an outcome is warranted for AIN of unknown aetiology. TRIAL REGISTRATION: Sri Lanka Clinical Trial Registry SLCTR/2014/007, Registered on the 31st of March 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Badurdeen Z, Ratnatunga N, Abeysekera T, et al. Randomized control trial of prednisolone and doxycycline in patients with acute interstitial nephritis of unknown aetiology. Trials. 2023. PMID: 36600250. doi:10.1186/s13063-022-07056-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。